Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4189-4193

  Powell, Steven ^a   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Brain metastasis; High dose interleukin 2; Metastatic melanoma; Retrospective study

Indexed keywords

INTERLEUKIN 2; LACTATE DEHYDROGENASE; TEMOZOLOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANURIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; BRAIN METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CONFUSION; CONJUNCTIVITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG MEGADOSE; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEUKOPENIA; LUNG EDEMA; MALE; MELANOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RIGOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-2; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71949109531     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Houghton A, Coit D, Bloomer W et al: NCCN melanoma practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 12(7A): 153-177, 1998.
2. DeVita VT, Hellman S and Rosenberg SA: Biologic Therapy of Cancer. Philadelphia: JB Lippincott, 1995.
3. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15): 889-897, 1987.
4. Parkinson DR, Abrams JS, Wiernik PH et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8(10): 1650-1656, 1990. (Pubitemid 20334319)
5. Atkins MB, Lotze MT, Dutcher JP et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7): 2105-2116, 1999.
6. Rosenberg SA, Yang JC, White DE et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228(3): 307-319, 1998.
7. Mekhail T, Wood L and Bukowski R: Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs 14(5): 299-318, 2000.
8. Sampson JH, Carter JH Jr, Friedman AH et al: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1): 11-20, 1998.
9. Guirguis LM, Yang JC, White DE et al: Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25(1): 82-87, 2002.
10. Trotti A, Colevas AD, Setser A et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003. (Pubitemid 36962641)
11. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 458-481, 1958.
12. Hurst R, White DE, Heiss J et al: Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J Immunother 22(4): 356-362, 1999.
13. Kammula US, White DE and Rosenberg SA: Trends in the safety of high-dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83(4): 797-805, 1998.
14. Brega K, Robinson WA, Winston K et al: Surgical treatment of brain metastases in malignant melanoma. Cancer 66: 2105-2110, 1990.
15. Fife KM, Colman MH, Stevens GN et al: Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7): 1293-1300, 2004. (Pubitemid 41079844)
16. Mathieu D, Kondziolka D, Cooper PB et al: Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg 54: 241-247, 2007.
17. Tarhini A and Agarwala S: Management of brain metastases in patients with melanoma. Curr Opin Oncol 16: 161-166, 2004. (Pubitemid 38402531)
18. Agarwala SS, Kirkwood JM, Gore M et al: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22(11): 2101-2107, 2004. (Pubitemid 41095143)
19. Hwu WJ, Lis E, Menell JH et al: Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12): 2590-2597, 2005. (Pubitemid 40800539)